Summary:
Psychiatric Care and Research Center is conducting a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ALK5461 versus placebo, as add-on therapy in patients with Major Depression who are having an inadequate response to their current antidepressant. This is a new antidepressant with a novel mechanism of action.
Qualified Participants Must:
• Be between 18 and 70 years of age
•
Have an episode of depression lasting not longer than 2 years
•
Have no more than 2 antidepressant treatment failures during the current depressive episode
•
Not currently have to be on an antidepressant
•
Not have Schizophrenia, Bipolar Disorder, or Substance Abuse within the last 6 months
Qualified Participants May Receive:
Compensation for time and travel may be possible